Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

52 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Pathological Outcomes of Patients With Advanced Renal Cell Carcinoma Who Receive Nephrectomy Following Immunotherapy.
Panian J, Saidian A, Hakimi K, Ajmera A, Anderson WJ, Barata P, Berg S, Signoretti S, Lee Chang S, D'Andrea V, George D, Dzimitrowicz H, El Zarif T, Emamekhoo H, Gross E, Kilari D, Lam E, Lashgari I, Psutka S, Rauterkus GP, Shabaik A, Thapa B, Wang L, Weise N, Yim K, Zhang T, Derweesh I, McKay RR. Panian J, et al. Among authors: kilari d. Oncologist. 2023 Jun 27:oyad166. doi: 10.1093/oncolo/oyad166. Online ahead of print. Oncologist. 2023. PMID: 37368355 Free article.
Enzalutamide-Induced Feed-Forward Signaling Loop Promotes Therapy-Resistant Prostate Cancer Growth Providing an Exploitable Molecular Target for Jak2 Inhibitors.
Udhane V, Maranto C, Hoang DT, Gu L, Erickson A, Devi S, Talati PG, Banerjee A, Iczkowski KA, Jacobsohn K, See WA, Mirtti T, Kilari D, Nevalainen MT. Udhane V, et al. Among authors: kilari d. Mol Cancer Ther. 2020 Jan;19(1):231-246. doi: 10.1158/1535-7163.MCT-19-0508. Epub 2019 Sep 23. Mol Cancer Ther. 2020. PMID: 31548294 Free PMC article.
CDK12-Mutated Prostate Cancer: Clinical Outcomes With Standard Therapies and Immune Checkpoint Blockade.
Schweizer MT, Ha G, Gulati R, Brown LC, McKay RR, Dorff T, Hoge ACH, Reichel J, Vats P, Kilari D, Patel V, Oh WK, Chinnaiyan A, Pritchard CC, Armstrong AJ, Montgomery RB, Alva A. Schweizer MT, et al. Among authors: kilari d. JCO Precis Oncol. 2020;4:382-392. doi: 10.1200/po.19.00383. Epub 2020 Apr 21. JCO Precis Oncol. 2020. PMID: 32671317 Free PMC article.
Outcomes With First-Line PD-1/PD-L1 Inhibitor Monotherapy for Metastatic Renal Cell Carcinoma (mRCC): A Multi-Institutional Cohort.
Barata P, Hatton W, Desai A, Koshkin V, Jaeger E, Manogue C, Cotogno P, Light M, Lewis B, Layton J, Sartor O, Basu A, Kilari D, Emamekhoo H, Bilen MA. Barata P, et al. Among authors: kilari d. Front Oncol. 2020 Oct 22;10:581189. doi: 10.3389/fonc.2020.581189. eCollection 2020. Front Oncol. 2020. PMID: 33194712 Free PMC article.
PROMISE: a real-world clinical-genomic database to address knowledge gaps in prostate cancer.
Koshkin VS, Patel VG, Ali A, Bilen MA, Ravindranathan D, Park JJ, Kellezi O, Cieslik M, Shaya J, Cabal A, Brown L, Labriola M, Graham LS, Pritchard C, Tripathi A, Nusrat S, Barata P, Jang A, Chen SR, Garje R, Acharya L, Hwang C, Pilling A, Oh W, Jun T, Natesan D, Nguyen C, Kilari D, Pierro M, Thapa B, Cackowski F, Mack A, Heath E, Marshall CH, Tagawa ST, Halabi S, Schweizer MT, Armstrong A, Dorff T, Alva A, McKay R. Koshkin VS, et al. Among authors: kilari d. Prostate Cancer Prostatic Dis. 2022 Sep;25(3):388-396. doi: 10.1038/s41391-021-00433-1. Epub 2021 Aug 6. Prostate Cancer Prostatic Dis. 2022. PMID: 34363009 Free PMC article. Review.
Efficacy of enfortumab vedotin in advanced urothelial cancer: Analysis from the Urothelial Cancer Network to Investigate Therapeutic Experiences (UNITE) study.
Koshkin VS, Henderson N, James M, Natesan D, Freeman D, Nizam A, Su CT, Khaki AR, Osterman CK, Glover MJ, Chiang R, Makrakis D, Talukder R, Lemke E, Olsen TA, Jain J, Jang A, Ali A, Jindal T, Chou J, Friedlander TW, Hoimes C, Basu A, Zakharia Y, Barata PC, Bilen MA, Emamekhoo H, Davis NB, Shah SA, Milowsky MI, Gupta S, Campbell MT, Grivas P, Sonpavde GP, Kilari D, Alva AS. Koshkin VS, et al. Among authors: kilari d. Cancer. 2022 Mar 15;128(6):1194-1205. doi: 10.1002/cncr.34057. Epub 2021 Dec 9. Cancer. 2022. PMID: 34882781 Free article.
Cabozantinib Safety With Different Anticoagulants in Patients With Renal Cell Carcinoma.
Shayeb AM, McManus HD, Urman D, Jani C, Zhang T, Dizman N, Meza L, Sivakumar A, Gan CL, Barata P, Bilen MA, Gao X, Heng D, Pal S, Narra R, Kilari D, Kaymakcalan MD, McGregor B, Choueiri TK, McKay RR. Shayeb AM, et al. Among authors: kilari d. Clin Genitourin Cancer. 2023 Feb;21(1):55-62. doi: 10.1016/j.clgc.2022.10.013. Epub 2022 Nov 3. Clin Genitourin Cancer. 2023. PMID: 36411184
Concurrent durvalumab and radiation therapy (DUART) followed by adjuvant durvalumab in patients with localized urothelial cancer of bladder: results from phase II study, BTCRC-GU15-023.
Joshi M, Tuanquin L, Zhu J, Walter V, Schell T, Kaag M, Kilari D, Liao J, Holder SL, Emamekhoo H, Sankin A, Merrill S, Zheng H, Warrick J, Hauke R, Gartrel B, Stein M, Drabick J, Degraff DJ, Zakharia Y. Joshi M, et al. Among authors: kilari d. J Immunother Cancer. 2023 Feb;11(2):e006551. doi: 10.1136/jitc-2022-006551. J Immunother Cancer. 2023. PMID: 36822667 Free PMC article. Clinical Trial.
Comprehensive genomic profiling: Does timing matter?
Thapa B, Ahmed G, Szabo A, Kamgar M, Kilari D, Mehdi M, Menon S, Daniel S, Thompson J, Thomas J, George B. Thapa B, et al. Among authors: kilari d. Front Oncol. 2023 Feb 14;13:1025367. doi: 10.3389/fonc.2023.1025367. eCollection 2023. Front Oncol. 2023. PMID: 36865796 Free PMC article.
52 results